HBM HOLDINGS-B Independent Director Under Investigation by Chinese Securities Regulator

Stock News

May 13

HBM HOLDINGS-B (02142) announced that the company has been notified that its Independent Non-Executive Director, Dr. Ye Xiaoping, received an investigation notice from the China Securities Regulatory Commission (CSRC) on May 12, 2026. The notice pertains to alleged violations of information disclosure regulations related to shareholding changes in Hangzhou Tigermed Consulting Co., Ltd. (300347.SZ; 3347.HK). In accordance with the Securities Law of the People's Republic of China and the Administrative Penalty Law of the People's Republic of China, the CSRC has decided to initiate an investigation into Dr. Ye. Dr. Ye has stated he will fully cooperate with the CSRC's work and strictly fulfill information disclosure obligations as required by regulations. As an Independent Non-Executive Director, Dr. Ye is not involved in the day-to-day management or operations of the group. The company's board of directors believes the group's business operations remain normal and the aforementioned investigation will not affect the group's normal operations.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.atigrnexa.com/news/1162773877"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1162773877\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1162773877?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-13 12:30","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1162773877","market":"other","top_or_hot":-1,"title":"HBM HOLDINGS-B Independent Director Under Investigation by Chinese Securities Regulator","media":"Stock News","content":"<p>HBM HOLDINGS-B (02142) announced that the company has been notified that its Independent Non-Executive Director, Dr. Ye Xiaoping, received an investigation notice from the China Securities Regulatory Commission (CSRC) on May 12, 2026. The notice pertains to alleged violations of information disclosure regulations related to shareholding changes in Hangzhou Tigermed Consulting Co., Ltd. (300347.SZ; 3347.HK). In accordance with the Securities Law of the People's Republic of China and the Administrative Penalty Law of the People's Republic of China, the CSRC has decided to initiate an investigation into Dr. Ye. Dr. Ye has stated he will fully cooperate with the CSRC's work and strictly fulfill information disclosure obligations as required by regulations. As an Independent Non-Executive Director, Dr. Ye is not involved in the day-to-day management or operations of the group. The company's board of directors believes the group's business operations remain normal and the aforementioned investigation will not affect the group's normal operations.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>HBM HOLDINGS-B Independent Director Under Investigation by Chinese Securities Regulator</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHBM HOLDINGS-B Independent Director Under Investigation by Chinese Securities Regulator\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-05-13 12:30</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>HBM HOLDINGS-B (02142) announced that the company has been notified that its Independent Non-Executive Director, Dr. Ye Xiaoping, received an investigation notice from the China Securities Regulatory Commission (CSRC) on May 12, 2026. The notice pertains to alleged violations of information disclosure regulations related to shareholding changes in Hangzhou Tigermed Consulting Co., Ltd. (300347.SZ; 3347.HK). In accordance with the Securities Law of the People's Republic of China and the Administrative Penalty Law of the People's Republic of China, the CSRC has decided to initiate an investigation into Dr. Ye. Dr. Ye has stated he will fully cooperate with the CSRC's work and strictly fulfill information disclosure obligations as required by regulations. As an Independent Non-Executive Director, Dr. Ye is not involved in the day-to-day management or operations of the group. The company's board of directors believes the group's business operations remain normal and the aforementioned investigation will not affect the group's normal operations.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02142","symbol_name":"和铂医药-B","start_time":0,"source_url":"","article_id":"1162773877","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1162773877","pubTimestamp":1778646618,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"HBM HOLDINGS-B (02142) announced that the company has been notified that its Independent Non-Executive Director, Dr. Ye Xiaoping, received an investigation notice from the China Securities Regulatory...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02142":"和铂医药-B","BK1574":"生物医药B类股","BK1583":"高瓴概念","BK1161":"生物科技"},"translate_title":"HBM HOLDINGS-B独立董事被中国证券监管机构调查","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02142":1},"content_text":"HBM HOLDINGS-B (02142) announced that the company has been notified that its Independent Non-Executive Director, Dr. Ye Xiaoping, received an investigation notice from the China Securities Regulatory Commission (CSRC) on May 12, 2026. The notice pertains to alleged violations of information disclosure regulations related to shareholding changes in Hangzhou Tigermed Consulting Co., Ltd. (300347.SZ; 3347.HK). In accordance with the Securities Law of the People's Republic of China and the Administrative Penalty Law of the People's Republic of China, the CSRC has decided to initiate an investigation into Dr. Ye. Dr. Ye has stated he will fully cooperate with the CSRC's work and strictly fulfill information disclosure obligations as required by regulations. As an Independent Non-Executive Director, Dr. Ye is not involved in the day-to-day management or operations of the group. The company's board of directors believes the group's business operations remain normal and the aforementioned investigation will not affect the group's normal operations.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"-1","news_tag":"executive","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}